---
layout: default
title: Apremilast
parent: 僅模型預測 (L5)
nav_order: 81
evidence_level: L5
indication_count: 0
---

# Apremilast
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Apremilast: Drug Repurposing Evaluation — TxGNN Predictions Pending

## One-Sentence Summary

Apremilast (DrugBank: DB05676) is a selective phosphodiesterase 4 (PDE4) inhibitor with established use in inflammatory conditions such as psoriatic arthritis and plaque psoriasis, and is confirmed as marketed in Malaysia with 3 registered products. However, the current Evidence Pack contains **no TxGNN-generated new indication predictions**, and critical data — including regulatory label details, safety warnings, and mechanism of action — were not retrieved in this collection cycle. A complete drug repurposing evaluation cannot be issued until these gaps are resolved; a **Hold** decision is recommended pending re-collection.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not retrieved — regulatory label text absent from this Evidence Pack |
| Predicted New Indication | **Pending** — no TxGNN predictions present in this Evidence Pack |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

This section cannot be completed in the standard form because no TxGNN-predicted target indication is available in the current Evidence Pack (`predicted_indications: []`).

From publicly available pharmacological knowledge, Apremilast is a small-molecule PDE4 inhibitor that raises intracellular cyclic AMP (cAMP) levels, broadly modulating the production of inflammatory and anti-inflammatory mediators (e.g., reducing TNF-α, IL-17, IL-23 while increasing IL-10). This mechanism of action has potential relevance across a wide spectrum of chronic inflammatory diseases beyond its currently approved uses.

Once TxGNN predictions are generated, this section will assess the mechanistic plausibility of the top-ranked candidate indication(s) and their relationship to the approved inflammatory indication cluster.

---

## Malaysia Market Information

The Evidence Pack records **3 registered products** in Malaysia (NPRA query status: success), but all product-level fields — authorisation number, product name, dosage form, manufacturer, and approved indication text — were returned as empty in this collection run. The table below cannot be populated until NPRA registration details are re-queried.

| Authorisation Number | Product Name | Dosage Form | Approved Indication |
|----------------------|--------------|-------------|---------------------|
| *(not retrieved)* | *(not retrieved)* | *(not retrieved)* | *(not retrieved)* |

**Action required:** Re-query NPRA with drug name "APREMILAST" and retrieve full product detail records for all 3 licences.

---

## Safety Considerations

Please refer to the package insert for safety information. Key warnings and contraindications were identified as a **Blocking** data gap (DG001) and were not retrieved in this evaluation cycle. No drug-drug interaction records were found in the DDI query (result: `not_found`, 0 interactions).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is missing the three minimum requirements for a repurposing evaluation — TxGNN target indication predictions, populated regulatory label data, and safety information — making it impossible to assess therapeutic potential, mechanistic plausibility, or risk profile at this time.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Download and parse the NPRA / TFDA package insert PDF for Apremilast to extract key warnings and contraindications; this must be resolved before any safety assessment can begin
- **[High — DG002]** Query the DrugBank API for DB05676 to retrieve the full mechanism of action (MOA) description
- **[Required]** Run the TxGNN model pipeline for Apremilast (DB05676) to generate ranked new-indication predictions; without predictions, no repurposing target exists to evaluate
- **[Required]** Re-query NPRA registration database to retrieve complete product details (authorisation numbers, product names, dosage forms, approved indications) for all 3 Malaysian licences
- **[Follow-up]** Once a target indication is identified, run ClinicalTrials.gov and PubMed evidence collectors against the drug–disease pair to populate the clinical trial and literature evidence sections
- **[Follow-up]** Reassign Evidence Level (L1–L5) and upgrade the decision recommendation (Go / Proceed with Guardrails) after all gaps above are closed

---

> ⚠️ **Disclaimer:** This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

